ACD856 (NeuroRestore) is a revolutionary molecule: a positive allosteric modulator (PAM) of Trk receptors. No other known synthetic or natural molecule does this.
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
İşlem aktif
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, alım satım veya diğer türden tavsiye veya öneriler anlamına gelmez ve teşkil etmez. Kullanım Koşulları bölümünde daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, alım satım veya diğer türden tavsiye veya öneriler anlamına gelmez ve teşkil etmez. Kullanım Koşulları bölümünde daha fazlasını okuyun.